Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (March 2021)
35 slides from Genprex's investor presentation, Mar 2, 2021
Slide 1: Reprogramming the Course of Cancer and Diabetes
©) Genprex’ REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX Updated March 2, 2021
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘Statements concained inthis presentation regarding matersthatarenot historia fats ar “forward-loolngstatements within the meaning ofthe Privae Secures Litigation Reform Actof 1985. Because such statements are subjecto risks anguncertainls, cial results may ber material ro
Slide 3: GNPX at a Glance
GNPX AT A GLANCE 10-DAY AVG SHARES Genprex. Ine. GNPX Nasdaq $538 254M 11M 47276764 $56,111,196 YeAsofMorch 1,2021. 2: Based on dosing price 2: of March 1, 2021 and pro-formashares outstanding a: of February 11,2021. ‘Gosh ond shares outstanding os of September 30, 2020 0n a proformo os odjusted bas
Slide 4: Major Competitive Advantages
MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM, Our non-vral Oncoprex® nancparticedelvey system i designed to deliver variety of therapeutic genestofightcancer.Datsingicate {hat ourleae drug candidate, REQOSEA” mmunogene therapy, may be combed witha number otapprovedcance drugs and nat may be ef
Slide 5: Executive Summary
EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM DEMONSTRATED CLINICAL ACHIEVEMENT FIRST SYSTEMIC GENE THERAPY . INITIATING TWO LUNG CANCER TRIALS USED FOR CANCER IN HUMANS IN 2021 LARGE MARKETS AND UNMET NEED WORLD-CLASS ACADEMIC PARTNERS. COMBINATION TRIALS WITH TOP : SELLING C
Slide 6: Fast Track Designation
FAST TRACK DESIGNATION * Genprex received Fast Track Designation (70) for REQORSA + AstraZeneca’s ‘Tagrisso for non-small cell lung cancer (NSCLC) patients that progressed on Tagrsso. ‘Tagrisso had $48+ worldwide gross sales in 2020, and itis Astrazeneca’: highest grossing product. FID is for therap
Slide 7: Research and Development Pipeline
© Genprex RESEARCH AND DEVELOPMENT PIPELINE UNICAL © CUINICAL——— CLINICAL DISCOVERY PRECLINICAL " AL uma EQORSA™ TARGETED THERAPIES <om i Tr ‘eQORsA™ + muMuNorneRAmts ‘cctcimn:2 > ‘VARIOUS ONCOLOGY TARGETS cxconnrccans ED — HE ss ronnaiooiatn Nasaaqi GNPX
Slide 8: Acclaim-1
g] Acclaim -1 REQORSA in combination with AstraZeneca's Tagrisso for NSCLC Patients with Stage 4, EGFR mutant NSCLC whose disease progressed after Tagrisso “15 US. sites -92 patients Phaze 1: 9-18 patente Phage 2:74 pavents Interim analysis at 51 events (Le. disease progression or death) Initiating
Slide 9: Acclaim-1 Endpoints
lili Acclaim -1 PRIMARY ENDPOINT + Dose limiting toxicity 1 + 343 dose escalation of, REQORSA in combination with Tagriso E ee PRIMARY ENDPOINT SECONDARY ENDPOINTS. Zz + Progression free survival (PFS) + Overall response rate og + Randomized 1:1, open-label, improvement of ‘combination Overall survi
Slide 10: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS. ‘+ Genprex’s oncology combination treatment ‘= Gene therapy drug candidate addresses Type 1 and approach utilizes targeted therapies and Type 2 diabetes. immunotherapies. ‘© May reduce or eliminate daily burden of chec
Slide 11: Oncology Program
Slide 12: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS MOST L%.. CANCER TAGRISSO® 2020 SALES NSCLC represents the majority of all lung cancers. ‘AstraZeneca’s highest grossing product. WORLDWIDE CASES KEYTRUDA® 2020 SALES More than two million cases per year worldwide. Merck's highest grossing product. STATES
Slide 13: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM GENES Multiple tumor SYNERGIES suppressor genes Modern approach using combination therapy ‘CANCERS Genetic mutations found in other cancers Genprex
Slide 14: Oncoprex Nanoparticle Delivery System
ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Positively charged TUSC2 gene ranopartcle Cassette So La! ° > > > e i} Negatively charged cancer cell Nanoparticle attaches Cancer killing genes Cell death to cancer cel Integrate into cell Ournon-viral, biodegr
Slide 15: Targeting Negative Surface Charges of Cancer Cells
TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN IDEAL MEANS TO SELECTIVELY TARGET CANCER CELLS + The activities of glucose metabolism have a profound impact on the surface of cancer cells + Elevated glycolysis in cancer cells lead toa higher secretion of lactate + Secreted lactate fons remove
Slide 16: REQORSA Targets Cancer at Its Core
REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS — MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Genp: ‘Nasdagy GNPX
Slide 17: TUSC2 Inhibits Key Cell Signaling
TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS coer ‘nope Simi Oncogenic Stress Nasaaqi GNPX
Slide 18: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM Immunomodulation of Carbo + Pembro + TUSC2 demonstrates rationale for the Acclaim-1 and Acclaim-2clinical trials, ‘treating patients who show progression after treatment with Tagrisso or Keytruda. Note: Treg ond Myeloidcals ore Immunozuppressive A rete Tet (Luna)
Slide 19: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n Maximum Tolerated D
Slide 20: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS Positive (exon 18420) Complete Response chemo 3 Negative 24% regression Target Lesion ‘Chemo /ant-?D1 2 20% regression one Target Lesion Negatwve "i repression a Target Lesion iene inten u Positive (exon
Slide 21: REQORSA + Tarceva Combination: Swimmer Plot
EGFR status/mutation REQORSA + TARCEVA COMBINATION ‘Swimmer Plot of Best Response, with Time on Study Negative -| Negative 4 Positive (exon 18+20) 4 Negative 4 Negative 4 Negative Negative Negative + Positive (exon 21) 4 Negative -] Negative 4 Positive (exon 21) + sD * Chemotherapy ‘4 Chemotherapy+i
Slide 22: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER ‘on Lung Metastasis Mode! ‘rusca-treates a TUSC2+ant-PD1 exhibit greater antitumor activity than eee eee either agent alone or control. checkpoint blockade alone. ) Genprex azaagi
Slide 23: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda REQORSA + Keytruda + Chemo Strong antitumor immune responses of anti-PD1 were REQORSAtanti-PD1-+chemo combination resulted found against PDX tumors developed in
Slide 24: Diabetes Program
DIABETES PROGRAM
Slide 25: Diabetic Patients in Need of Modern Therapy
DIABETIC PATIENTS IN NEED OF MODERN THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S', or 10 percent of the U.S. population. May replace daily burden of blood glucose ‘monitoring and insulin replacement t
Slide 26: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an AAV vector to deliver the Pdc1 and MafAgenes to the pancreas. Transforms alpha cells inthe pancreas into functional beta-like ces, which can produce insulin but are distinct en
Slide 27: Key Milestones Through 2021 & Beyond
KEY MILESTONES THROUGH 2021 & BEYOND Receive anticipated U.S. Food and Drug Administration (FDA) clearance for the Acclaim clinical als. Dose the first patent in each of the Acclaim clinical tials ‘Announce interim data from the Acclaim clinical ils Report prectncal data related to our Sponsored Res
Slide 28: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS rove raseog — MEEURSCEECOWOnE’ UieuceL 34s prasex.2)_557on fecal ‘Lymphocytic Leukemia ovo TRepeutes ROH rasong — ELSCOKTETAL FE! areas savin Pres) —_st028ion a nasdaq soloTumorstetema PERERA zesty 53.1 Bon Twrningeant ae nasdaq nscLCanasotseumons REBSUEGINE.
Slide 29: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman, President & Chief Executive Officer + 30+ yearsof expertise in corporate la, including ‘corporate governance, in bictech industry + Former ovner of secures broker dealer firm MICHAEL REDMAN Executive VP & Chief Operating Officer + 20+ year
Slide 30: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, Intellectual Property and Licensing + 20+ yearsof expertsein biotech IP law, business evelopment leensingtransactions + Seasoned! executive and arerney SHANNON INMAN, Vice President of Global Clinical Operations + 20+ years
Slide 31: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD. JACK A. ROTH MD. FACS, Chairman Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracicand Cardiovascular Surgery: Chief, Section of Thoracie Molecular Oncology; Professor of Molecular and Cellular Oncology: UT MD Andarson Cancer Center
Slide 32: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD MICHAEL MORSE MD, MHS, FACP- + Professor of Medicine, Diision of Medical Oncology Inthe Deparoment of Surgery at Duke University + Research expertise in targeted therapies and Immunotherapies for cancer ANDREW BECKER MD, PHD. + President and Founder, Becker Phar
Slide 33: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board + 20+ yearsof expertise in corporate la, including ‘corporate governance, in biotech industry + Former onner of zecurties broker desler frm JOSE A. MORENO TOSCANO, Board Director + Chief Executive Officer, LFB USA ne + 20+ year
Slide 34: We Believe in a Future of 21st Century Gene Therapies
WE BELIEVE 215T CENTURY GENE THERAPIES. MARKET GAPS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS SCALING UP MANUFACTURING PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS.
Slide 35: Genprex Contact Information
© Genprex NASDAQ: GNPX 1601 Trinity St, Bldg B, #3.312.09, Austin, Texas 78712 (877)774-GNPX | investors@genprex.com azaagiGNPx